Search
miltefosine (Impavido)
FDA-approved March 2014.
Indications:
- treatment of leishmaniasis
- visceral leishmaniasis
- cutaneous leishmaniasis
- mucocutaneous leishmaniasis
Dosage:
- oral
Contraindications:
- pregnancy
Adverse effects:
- nausea
- vomiting
- diarrhea
- abdominal pain
- decreased appetite
- headache
- dizziness
- drowsiness
- itching
- increased serum transaminases
- increased serum creatinine
General
antiparasitic agent
Database Correlations
PUBCHEM cid=3599
References
- FDA News Release: March 19, 2014
FDA approves Impavido to treat tropical disease leishmaniasis.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm389671.htm